A predominant cleaved form of pro-glucagon expressed in the intestine. GLP-1 [7-36]amide is promptly released from the gut after oral ingestion of a meal where it slows gastric emptying and exerts a powerful insulinotropic action leading to elevated serum insulin levels. GLP-1 [7-36] amide promotes satiety and reduces food intake in patients with diabetes mellitus type 2 and has been suggested to have therapeutic potential in the treatment of NIDDM. It has been reported that human pancreatic endocrine tumors contain molecular forms of GLP-1 which resemble those expressed in the small intestine, rather than in their tissue of origin. Serves as a control peptide for Anti-GLP-1 [7-36] Amide (BML-GA1178). Blocks immunoreactivity at 10 nmol per ml diluted antibody. Product Specification Alternative Name:GLP 1 (7-36) amide Sequence:H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 MW:3297.7 Appearance:Lyophilized solid. Solubility:Soluble in water at 1mg/mL. Long Term Storage:-20°C